Bulletin
Investor Alert

London Markets Open in:

Philip van Doorn

Deep Dive Archives | Email alerts

Feb. 25, 2015, 4:26 p.m. EST

10 cheapest stocks in the Nasdaq’s hottest sector

A handful of health-care stocks have doubled this year, and one has quadrupled

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    NASDAQ Composite Index (COMP)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Philip van Doorn, MarketWatch


Shutterstock
Eagle Pharmaceuticals is one of the best-performing Nasdaq stocks this year, rising 119%, and it is also among the 10 cheapest.

Health care is the best-performing sector in the Nasdaq this year, and it may not be too late to buy stocks at attractive prices.

The Nasdaq Composite Index /zigman2/quotes/210598365/realtime COMP -3.52%  is close to passing the 5,000 mark, returning to a high set way back in 2000 before the dot-com bubble burst. This time around, the stock market doesn’t appear as “frothy” as it did before that crash, according to Mark Hulbert. It’s also interesting to note that the Nasdaq has outperformed other broad indices this year, as well as during 2014 and over the past three-year, five-year and 10-year periods.

This week we published lists of the top 10 Nasdaq stocks for the time periods listed above.

Among the Nasdaq’s 10 broad benchmark sectors, the strongest this year has been health care, which is up 6.2%, compared with a 4.9% return for the Nasdaq and a 2.8% return for the large-cap S&P 500 Index /zigman2/quotes/210599714/realtime SPX -2.45% .


FactSet
The Nasdaq Composite Index has outperformed the S&P 500 this year, last year and over the past three, five and 10 years.

Looking at the Nasdaq chart above, the action appears healthy, as the 20-day and 50-day moving averages are well above the 200-day average, and both the 20-day and 50-day averages are on upward curves.

Here’s a similar chart for the Nasdaq U.S. Benchmark Health Care Index:


FactSet
The Nasdaq Health Care Index is up 6.2% this year.

Nasdaq’s health-care winners

When looking at the best performers among Nasdaq stocks, especially for relatively short periods, the numbers can be astounding. But there’s tremendous volatility as companies try to bring new technologies and products to the market.

Here are this year’s 10 strongest performers among Nasdaq stocks in various health-care industries, along with returns for previous periods:

Company Ticker Industry Total return - YTD Total return - 2014 Total return - 3 years Total return - 5 years
Capnia Inc. Medical Specialties 336% N/A N/A N/A
Anthera Pharmaceuticals Inc. /zigman2/quotes/200523620/composite ANTH Biotechnology 213% -49% -91% N/A
Semler Scientific Inc. /zigman2/quotes/201267132/composite SMLR Medical Specialties 142% N/A N/A N/A
Egalet Corp. Pharmaceuticals 135% N/A N/A N/A
Eagle Pharmaceuticals Inc. /zigman2/quotes/200611523/composite EGRX Pharmaceuticals 119% N/A N/A N/A
Foundation Medicine Inc. Biotechnology 117% -7% N/A N/A
Celluar Biomedicine Group Inc. Biotechnology 116% 153% 249% 166%
Curis Inc. /zigman2/quotes/207276322/composite CRIS Biotechnology 110% -47% -31% 26%
Apricus Biosciences Inc. Medical Specialties 107% -62% -40% -72%
Echo Therapeutics Inc. /zigman2/quotes/205706544/composite ECTE Medical Specialties 106% -57% -84% -85%
Total returns assume reinvestment of dividends. Source: FactSet

As you can see, most of those companies have been listed rather recently, and the longer-term returns show plenty of risk. Those stocks shouldn’t be taken lightly. You must be willing to do research on your own, while also reading any research reports your broker or adviser can provide.

Another interesting thing to note is that the companies above aren’t necessarily expected to turn operating profits any time soon. But there is one exception.

Cheapest Nasdaq health-care stocks

Here’s a list of the 10 cheapest Nasdaq health-care stocks, based on consensus 2016 earnings estimates among analysts polled by FactSet:

Company Ticker Industry Closing price - Feb. 23 Consensus 2016 EPS estimate Forward P/E Total return - YTD
AMAG Pharmaceuticals Inc. Biotechnology $43.93 $7.41 5.9 3%
Rockwell Medical Inc. /zigman2/quotes/208743423/composite RMTI Medical Specialties $10.34 $1.72 6.0 1%
Supernus Pharmaceuticals Inc. /zigman2/quotes/203126024/composite SUPN Pharmaceuticals $8.75 $1.25 7.0 5%
Vascular Biogenics Ltd. /zigman2/quotes/205948128/composite VBLT Biotechnology $4.08 $0.57 7.1 -31%
Flamel Technologies SA Sponsored ADR Medical Specialties $14.33 $1.90 7.6 -16%
PDL BioPharma Inc. Biotechnology $7.34 $0.79 9.4 -5%
Eagle Pharmaceuticals Inc. /zigman2/quotes/200611523/composite EGRX Pharmaceuticals $34.00 $3.60 9.4 119%
Pozen Inc. Pharmaceuticals $7.39 $0.77 9.6 -8%
LifeVantage Corp. /zigman2/quotes/208443358/composite LFVN Pharmaceuticals $0.96 $0.10 9.6 -26%
Enanta Pharmaceuticals Inc. /zigman2/quotes/209139157/composite ENTA Biotechnology $35.55 $3.64 9.8 -30%
Source: FactSet

Eagle Pharmaceuticals Inc. /zigman2/quotes/200611523/composite EGRX +0.22%  of Woodcliff Lake, N.J., is the only company appearing on both lists. Of course, a company doesn’t need to have prospects for near-term profitability for investors to make a killing on its stock, but the expected profits could make the investment less risky.

Eagle Pharmaceuticals develops products and services designed to make injectable drugs more effective and safer, and to make the delivery and administration of the drugs more efficient.

The company’s stock shot up 24% on Feb. 17 and then another 41% the next day, after the company said it had entered into a licensing agreement with Teva Pharmaceuticals Industries Ltd. /zigman2/quotes/205657894/composite TEVA -2.83% , through which Eagle would receive an immediate payment of $30 million for the development of its rapid infusion bendamustine product. Eagle may receive another $90 million in additional payments from Teva when it hits certain milestones, and also will receive “double-digit royalties” from Teva’s sales of the product.

All three sell-side analysts covering Eagle Pharmaceuticals rate the shares “buy,” or overweight, according to FactSet.

Piper Jaffray analyst David Amsellem on Feb. 18 raised his price target for the shares to $41 from $23 and estimated the company would earn $2.74 a share in 2016. In a note to clients, Amsellem wrote that the deal with Teva “enables a potential near-term launch (possibly in the second half of 2015), and opens EGRX up to an attractive royalty stream, particularly considering that visibility on sustained exclusivity for EP-3102 [the rapid infusion bendamustine product] (or relatively limited competition at worst over the long-term) in our view is strong.”

/zigman2/quotes/210598365/realtime
US : U.S.: Nasdaq
13,119.43
-478.54 -3.52%
Volume: 5.47M
Feb. 25, 2021 5:16p
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,829.34
-96.09 -2.45%
Volume: 2.92B
Feb. 25, 2021 5:19p
loading...
/zigman2/quotes/200523620/composite
US : U.S.: OTC
$ 0.11
-0.0066 -5.71%
Volume: 415,291
Feb. 25, 2021 3:48p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$719,923
Rev. per Employee
N/A
loading...
/zigman2/quotes/201267132/composite
US : U.S.: OTC
$ 103.00
-1.82 -1.74%
Volume: 13,233
Feb. 25, 2021 3:58p
P/E Ratio
72.51
Dividend Yield
N/A
Market Cap
$697.90 million
Rev. per Employee
$489,060
loading...
/zigman2/quotes/200611523/composite
US : U.S.: Nasdaq
$ 45.78
+0.10 +0.22%
Volume: 111,716
Feb. 25, 2021 4:00p
P/E Ratio
129.18
Dividend Yield
N/A
Market Cap
$595.22 million
Rev. per Employee
$1.81M
loading...
/zigman2/quotes/207276322/composite
US : U.S.: Nasdaq
$ 9.75
-0.18 -1.81%
Volume: 1.14M
Feb. 25, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$838.78 million
Rev. per Employee
$357,286
loading...
/zigman2/quotes/205706544/composite
US : U.S.: OTC
$ 0.05
0.00 0.00%
Volume: 248,928
Feb. 25, 2021 3:33p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
N/A
Rev. per Employee
N/A
loading...
/zigman2/quotes/208743423/composite
US : U.S.: Nasdaq
$ 1.40
-0.09 -6.04%
Volume: 1.24M
Feb. 25, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$139.42 million
Rev. per Employee
$205,026
loading...
/zigman2/quotes/203126024/composite
US : U.S.: Nasdaq
$ 29.45
-1.49 -4.82%
Volume: 696,811
Feb. 25, 2021 4:00p
P/E Ratio
12.22
Dividend Yield
N/A
Market Cap
$1.63 billion
Rev. per Employee
$846,455
loading...
/zigman2/quotes/205948128/composite
US : U.S.: Nasdaq
$ 1.82
-0.14 -7.14%
Volume: 1.58M
Feb. 25, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$94.45 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/200611523/composite
US : U.S.: Nasdaq
$ 45.78
+0.10 +0.22%
Volume: 111,716
Feb. 25, 2021 4:00p
P/E Ratio
129.18
Dividend Yield
N/A
Market Cap
$595.22 million
Rev. per Employee
$1.81M
loading...
/zigman2/quotes/208443358/composite
US : U.S.: Nasdaq
$ 8.87
+0.03 +0.34%
Volume: 66,384
Feb. 25, 2021 4:00p
P/E Ratio
11.03
Dividend Yield
N/A
Market Cap
$125.23 million
Rev. per Employee
$942,976
loading...
/zigman2/quotes/209139157/composite
US : U.S.: Nasdaq
$ 50.58
-1.14 -2.20%
Volume: 100,793
Feb. 25, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.04 billion
Rev. per Employee
$868,603
loading...
/zigman2/quotes/200611523/composite
US : U.S.: Nasdaq
$ 45.78
+0.10 +0.22%
Volume: 111,716
Feb. 25, 2021 4:00p
P/E Ratio
129.18
Dividend Yield
N/A
Market Cap
$595.22 million
Rev. per Employee
$1.81M
loading...
/zigman2/quotes/205657894/composite
US : U.S.: NYSE
$ 11.00
-0.32 -2.83%
Volume: 9.90M
Feb. 25, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$12.09 billion
Rev. per Employee
$422,386
loading...

Philip van Doorn covers various investment and industry topics. He has previously worked as a senior analyst at TheStreet.com. He also has experience in community banking and as a credit analyst at the Federal Home Loan Bank of New York.

This Story has 0 Comments
Be the first to comment
More News In
Investing

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.